Sagimet Biosciences Inc. Series A Common Stock (SGMT)

Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $633M; returns 1 day -3.7%, 1 week +19.5%, 1 year +30.7%.

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of first-in-class fatty acid synthase (FASN) inhibitors designed to treat metabolic and fibrotic diseases. The company’s lead candidate, denifanstat, is an oral, once-daily selective FASN inhibitor targeting the overproduction of palmitate, a driver of liver fat and fibrosis.

Groups SGMT belongs to

• Clinical Stage Biopharma
• Biotechnology
• NASH
• Metabolic Disorders
• Fibrosis
• Healthcare
• Liver Disease
• Clinical Stage
• Pharmaceuticals

SGMT financial model: income statement, cash flow and balance sheet